Ongoing use can help sustain weight loss and support metabolic health, provided any side effects are properly managed with professional guidance
Browse all Peptides & GLP-1 education Medical and Editorial Standards Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims
It should not be used by individuals with a personal or family history of medullary thyroid carcinoma (a type of thyroid cancer) or those with multiple endocrine neoplasia syndrome type 2 (MEN 2)
The AACE/ACE, in contrast to the ADA, provides several monotherapy options that are recommended in the following order according to the strength of each recommendation: metformin, GLP-1 receptor agonist, SGLT-2 inhibitor, DPP-4 inhibitor, thiazolidinedione, -glucosidase inhibitor, and an insulin secretagogue (a sulfonylurea or meglitinide)
Clinical trials show semaglutide reduces body weight by 915% over 68 weeks when combined with lifestyle changes
